August 31, 2020 11:00 AM EDTUpdated 05:27 PM

Novartis says its Soliris add-on might be able to replace the Alexion drug altogether. But is it too late?

Amber Tong

Novartis says one of its top emerging drugs spotlighted by Vas Narasimhan has come through in a Phase II trial for paroxysmal nocturnal hemoglobinuria, burnishing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis says its Soliris add-on might be able to replace the Alexion drug altogether. But is it too late?

Amber Tong

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

No­var­tis says its Soliris add-on might be able to re­place the Alex­ion drug al­to­geth­er. But is it too late?

Amber Tong

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Novartis says its Soliris add-on might be able to replace the Alexion drug altogether. But is it too late?

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life